Targeting the Synapse in Alzheimer's Disease

Area of Science:

• Neuroscience
• Pathology
• Pharmacology

Background:

• Dynamic synaptic changes are crucial for brain function.
• Alzheimer's Disease (AD) treatments often target beta-amyloid and tau, but synaptic health is also critical.
• Synaptic dysfunction may link AD pathologies to symptoms and occur early in the disease.

Purpose of the Study:

• To review evidence for early neuroplastic deficits in Alzheimer's Disease.
• To explore how amyloid and tau pathologies influence synaptic changes.
• To discuss the synapse as a therapeutic target for AD.

Main Methods:

• Review of existing scientific literature on neuroplasticity and Alzheimer's Disease.
• Analysis of the interplay between synaptic degeneration, maintenance, and compensation.
• Examination of direct and indirect effects of amyloid and tau on synapses.

Main Results:

• Neuroplastic deficits, including changes in synaptic density, are prevalent early in AD.
• Synaptic levels are dynamically regulated by degeneration and compensatory mechanisms.
• Amyloid and tau impact synaptic integrity through direct and indirect pathways like inflammation and energetics.

Conclusions:

• Synaptic dysfunction is a common pathway linking AD pathologies to cognitive decline.
• Targeting neuroplasticity offers a complementary therapeutic strategy for AD.
• Restoring synapse dynamics may normalize cognitive function in AD and other neurodegenerative diseases.